Results 121 to 130 of about 42,377 (214)

Pharmacokinetics of 2 mg/kg Bupivacaine in a Rectus Abdominis Sheath Block in Horses

open access: yesJournal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT Administering large volumes of bupivacaine in the rectus abdominis sheath (RAS) block in horses could cause local anesthetic toxicity. This study aimed to evaluate the pharmacokinetics of 2 mg/kg bupivacaine in RAS blocks and the associated toxicity risk.
Daniel M. Sakai   +7 more
wiley   +1 more source

Characteristics of sudden cardiac arrest during endurance racing: a decade of the Paris registry. [PDF]

open access: yesEuropace
Chocron R   +20 more
europepmc   +1 more source

Utilization and Prognosis of Cardiac Device Implantation in AL Versus ATTR Amyloidosis

open access: yesPacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Introduction Cardiac amyloidosis can cause congestive heart failure, arrhythmias, and heart blocks, which frequently require cardiac device implantation (CDI). However, the differences between light chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis CDI requirements are unknown. Methods A retrospective analysis was conducted using the
Bilal Hussain   +7 more
wiley   +1 more source

Incidence and Determinants of Implantable Cardioverter‐Defibrillator Therapy With Loss of and Impaired Consciousness

open access: yesPacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Introduction Implantable cardioverter‐defibrillators (ICDs) are important in the prevention of sudden cardiac death. However, some appropriate ICD therapies may be considered unnecessary, delivered when patients do not experience symptoms of hemodynamic instability such as loss of consciousness.
Alwin B. P. Noordman   +5 more
wiley   +1 more source

Trends in Mortalities due to Sudden Cardiac Arrest in the United States Population. [PDF]

open access: yesJ Arrhythm
Faheem MSB   +8 more
europepmc   +1 more source

Safety and Performance of INVICTA DF4 Ventricular Defibrillation Lead: Results From APOLLO Prospective Multicenter Study

open access: yesPacing and Clinical Electrophysiology, EarlyView.
Abstract Background Implantable cardioverter‐defibrillator (ICD) therapy relies on reliable right ventricular leads for pacing, sensing, and defibrillation. The INVICTA DF4 lead is an active‐fixation, quadripolar design intended to optimize implant workflow and long‐term safety and performance. Methods APOLLO was a prospective, multicenter, single‐arm,
Klaus K. Witte   +13 more
wiley   +1 more source

First Experience With Extravascular Implantable Cardioverter‐Defibrillator Under Deep Sedation

open access: yesPacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Background The Extravascular Implantable Cardioverter‐Defibrillator (EV‐ICD) utilizes a substernal lead to provide defibrillation and anti‐tachycardia pacing (ATP) while avoiding transvenous complications. General anesthesia (GA) was applied for implantation procedures in the EV‐ICD pivotal trial and is currently recommended by the ...
Nibras Soubh   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy